{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:37:13Z","timestamp":1790397433752,"version":"4.1.0"},"reference-count":36,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy of cefepime for use in infections caused by extended-spectrum beta-lactamase (ESBL)-producing organisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A PubMed literature search (May 2000 to June 2017) was performed using the keyword cefepime and the MeSH terms beta-lactamases, cephalosporinases, and Enterobacteriaceae infections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All human, English language studies evaluating cefepime use for the treatment of ESBL-producing Escherichia coli and Klebsiella pneumoniae infections were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Studies assessing the use of cefepime for ESBL infections are few, and clinical studies are limited by design and sample size. The largest pharmacokinetic\/pharmacodynamic study, a Monte Carlo simulation using data from the U.S. SENTRY antimicrobial surveillance program, evaluating cefepime use for infections due to ESBL-producing organisms found a 95% to 100% probability of target attainment with traditional cefepime dosing regimens. Most clinical studies found that patients treated with cefepime empirically and definitively had higher rates of mortality than those treated with carbapenems. However, in concordance with other studies reporting minimum inhibitory concentration (MIC) data, lower MICs were associated with lower mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Cefepime should be avoided for empiric treatment of suspected ESBL infections and should only be considered for definitive treatment if the MIC \u22641 \u00b5g\/mL. However, the site and severity of infection, local resistance patterns, and patient-specific risk factors should also help guide antimicrobial selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0897190017743134","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T21:30:21Z","timestamp":1511386221000},"page":"458-463","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["The Role of Cefepime in the Treatment of Extended-Spectrum Beta-Lactamase Infections"],"prefix":"10.1177","volume":"32","author":[{"given":"Hansita B.","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Feik School of Pharmacy, University of the Incarnate Word, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A.","family":"Lusk","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Feik School of Pharmacy, University of the Incarnate Word, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Cota","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Feik School of Pharmacy, University of the Incarnate Word, San Antonio, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"bibr1-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1177\/2049936113476284"},{"key":"bibr2-0897190017743134","first-page":"2012","volume":"625170","author":"Dhillon RH-P","year":"2012","journal-title":"Crit Care Res Pract"},{"key":"bibr3-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.03613-13"},{"key":"bibr4-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70041-0"},{"key":"bibr5-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm310"},{"key":"bibr6-0897190017743134","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-1-200401060-00008"},{"key":"bibr7-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1086\/591861"},{"key":"bibr8-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1086\/507962"},{"key":"bibr9-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1086\/319757"},{"key":"bibr10-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.12.1375"},{"key":"bibr11-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2005.09.011"},{"key":"bibr12-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.39.6.2206-2212.2001"},{"key":"bibr13-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt450"},{"key":"bibr14-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1046\/j.1469-0691.2000.00107.x"},{"key":"bibr15-0897190017743134","doi-asserted-by":"publisher","DOI":"10.4103\/0974-777X.68531"},{"key":"bibr16-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1592\/phco.21.6.583.34537"},{"key":"bibr17-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.11.3442-3447.2003"},{"key":"bibr18-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1643-1646.2003"},{"key":"bibr19-0897190017743134","unstructured":"Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. Wayne, PA: Clinical Laboratory Standards Institute; 2009:M100\u2013S19."},{"key":"bibr20-0897190017743134","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Twenty-third Informational Supplement M100-S23","author":"Clinical Laboratory Standards Institute","year":"2013"},{"key":"bibr21-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01290.x"},{"key":"bibr22-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01477-15"},{"key":"bibr23-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02365-12"},{"key":"bibr24-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.06.004"},{"key":"bibr25-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2005.01.005"},{"key":"bibr26-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.03.019"},{"key":"bibr27-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis916"},{"key":"bibr28-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05419-11"},{"key":"bibr29-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw132"},{"key":"bibr30-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01487-06"},{"key":"bibr31-0897190017743134","doi-asserted-by":"crossref","unstructured":"Seo YB, Lee J, Kim YK, et al. Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing\n                      Escherichia coli\n                      . BMC Infect Dis. 2017;17(1):404.","DOI":"10.1186\/s12879-017-2502-x"},{"key":"bibr32-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit383"},{"key":"bibr33-0897190017743134","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1. 2013. http:\/\/www.eucast.org. Updated March 10, 2017. Accessed May 30, 2017."},{"key":"bibr34-0897190017743134","first-page":"45","volume":"13","author":"Wu N","year":"2014","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"bibr35-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.10.011"},{"key":"bibr36-0897190017743134","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2015.02.030"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190017743134","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190017743134","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190017743134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:34:46Z","timestamp":1777509286000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190017743134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1177\/0897190017743134"],"URL":"https:\/\/doi.org\/10.1177\/0897190017743134","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,22]]}}}